20 Participants Needed

Vaginal Seeding for Cesarean Section Babies

(MOTHER SEED Trial)

NR
MS
AC
AE
AE
Overseen ByAndrea E Lee, MA, MLS
Age: 18 - 65
Sex: Female
Trial Phase: Phase < 1
Sponsor: Vanderbilt University Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether swabbing C-section babies with their mother's vaginal fluids can safely alter the bacteria in their noses. Researchers aim to determine if this process, known as vaginal seeding, impacts the early-life respiratory health of these babies. In the trial, some babies will receive the vaginal swab, while others will receive a sterile swab (placebo swab) for comparison. Mothers planning a scheduled C-section at Vanderbilt University Medical Center and who have undergone certain prenatal screenings might be suitable candidates. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on newborn health.

Do I need to stop my current medications to participate in the trial?

The trial does not specify if you need to stop taking your current medications. However, it excludes participants who have used certain medications like systemic antibiotics or immunosuppressive agents shortly before delivery, so it's best to discuss your specific medications with the trial team.

What prior data suggests that vaginal seeding is safe for cesarean-born children?

Research shows that vaginal seeding is under investigation for safety in newborns. This process involves swabbing infants born via cesarean section with their mother's vaginal fluids. Studies indicate that this can alter the community of bacteria, known as the microbiome, in these babies. For example, certain bacteria like Enterobacteriaceae decrease. Although research has focused on these bacterial changes, no major safety issues have emerged. However, more studies are needed to confirm these findings.

Since detailed safety data is not yet available, the trial's "not applicable" phase suggests it is considered low-risk, as early phases usually focus on safety. Participants in such trials help researchers better understand any potential risks or benefits.12345

Why are researchers excited about this trial?

Researchers are excited about the vaginal seeding technique for babies born via cesarean section because it has the potential to mimic the natural bacterial exposure that occurs during a vaginal birth. Most cesarean-born babies miss out on this initial exposure to beneficial bacteria, which can play a crucial role in developing their immune systems. By using a swab to transfer maternal vaginal fluids to the newborn, this method aims to introduce these beneficial microbes early on, possibly offering health benefits not typically available with the standard sterile environment of a cesarean delivery. This could lead to improved long-term health outcomes, such as a reduced risk of allergies and autoimmune conditions.

What evidence suggests that vaginal seeding is effective for modifying the URT microbiome in C-section babies?

Research shows that "vaginal seeding," which participants in this trial may receive, can help C-section babies develop a microbiome similar to those born naturally. This process involves gently wiping the baby with the mother's vaginal fluids. Some studies have found small changes in the gut bacteria of these babies, suggesting possible benefits. Evidence also indicates a reduction in certain bacteria, like Enterobacteriaceae, in babies who undergo this procedure. While it might not significantly affect allergy risks or growth, it is considered safe and could aid some aspects of development. Overall, more research is needed, but early results are promising for adjusting the microbiome of C-section-born babies.12356

Who Is on the Research Team?

CR

Christian Rosas-Salazar, MD, MPH

Principal Investigator

Vanderbilt University Medical Center

Are You a Good Fit for This Trial?

This trial is for healthy infants born by C-section at VUMC, with mothers aged 18-40 intending to breastfeed and have pediatric care at VUMC. Exclusions include maternal infections like HIV or hepatitis, fever before delivery, use of certain antibiotics or immunosuppressives near delivery time, labor complications, and serious infant health issues.

Inclusion Criteria

No intent to relocate outside the middle Tennessee region within 18-24 months of recruitment
Scheduled for a planned C-section due to a repeat C-section at VUMC (main campus only)
Intention to breastfeed partially or exclusively
See 4 more

Exclusion Criteria

Need for a switch from a planned C-section to an emergency C-section
I am currently taking antibiotics or drugs that suppress my immune system.
Onset of labor or rupture of membranes prior to delivery
See 16 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Immediately after birth

Intervention

Nose swabbing with either maternal vaginal secretions or a sterile swab is performed immediately after birth

Immediately following birth
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the intervention

6 months
Multiple visits at birth, ~2 days, ~5 days, ~4 weeks, and ~6 months of age

What Are the Treatments Tested in This Trial?

Interventions

  • Sterile Swab
  • Vaginal Seeding
Trial Overview The study tests if swabbing a newborn's nose with vaginal secretions after a C-section can safely alter the baby's upper respiratory microbiome. Infants are randomly assigned to receive either the vaginal seeding treatment or a sterile swab as control.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: Intervention GroupActive Control1 Intervention
Group II: Control GroupPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

In a study of 346 preterm breech infants, those delivered vaginally had better arterial cord blood pH and base excess compared to those delivered by cesarean section, suggesting a potentially better fetal outcome for vaginal deliveries.
The findings indicate that there is no clear advantage of routine cesarean section over vaginal delivery for preterm breech infants, as many parameters were comparable, and the data do not support a policy favoring cesarean delivery.
Comparison of fetal outcome in premature vaginal or cesarean breech delivery at 24-37 gestational weeks.Vidovics, M., Jacobs, VR., Fischer, T., et al.[2018]
A study involving 635 women who attempted vaginal birth after cesarean (VBAC) and 2593 control patients found that certain physician characteristics, such as lower cesarean rates and younger age, significantly increased the likelihood of successful VBAC.
Hospitals with high neonatal and obstetrical specialization also supported higher rates of VBAC, indicating that both physician and hospital factors play crucial roles in the adoption of this practice, which still shows considerable variability across different settings.
Factors influencing the practice of vaginal birth after cesarean section.Goldman, G., Pineault, R., Potvin, L., et al.[2019]
Children born via Cesarean section may face higher risks for health issues like allergies, asthma, and obesity, leading to interest in vaginal seeding as a potential solution.
Vaginal seeding aims to transfer the mother's vaginal microbiome to C-section infants, showing some promise in restoring microbial exposure, but there is currently insufficient evidence to confirm its health benefits, with ongoing studies needed.
Bacterial Baptism: Scientific, Medical, and Regulatory Issues Raised by Vaginal Seeding of C-Section-Born Babies.Mueller, NT., Hourigan, SK., Hoffmann, DE., et al.[2021]

Citations

Effects of vaginal microbiota transfer on the ...Overall, VMT is likely safe and may partially normalize neurodevelopment and the fecal microbiome in cesarean-delivered infants.
Can Vaginal Seeding at Birth Improve Health Outcomes of ...Studies have shown that vaginal seeding at birth partially restores the infant microbiome towards that of a vaginally delivered infant. More ...
Impact of vaginal seeding on the gut microbiome of infants ...Current evidence indicates modest changes in the gut microbiome of CS-born infants following VS. However, further clinical studies are necessary.
Maternal Bacterial Engraftment in Multiple Body Sites of ...Consistently, in our study, vaginal seeding of C-section-delivered neonates decreased the abundance of Enterobacteriaceae (15, 19). However, ...
Microbiome seeding - what's the evidence?“For infants born through cesarean delivery, vaginal seeding has no significant impacts on the gut microbiota, growth, or allergy risks ...
Vaginal SeedingA pilot study of 18 newborns (7 born vaginally and 11 by cesarean delivery) and their mothers was conducted in an attempt to partially restore the microbiota ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security